Product Data Sheet
Product Name:Lanifibranor (IVA337)
Cat. No.:GC31320
Chemical Properties
Cas No.927961-18-0
记一件有趣的事
Chemical
Name
N/A
Canonical
SMILES
销售巨人O=C(O)CCCC(N1S(=O)(C2=CC=C3N=CSC3=C2)=O)=CC4=C1C=CC(Cl)=C4 Formula C19H15ClN2O4S2M.Wt434.92
Solubility DMSO : 100 mg/mL (229.93 mM;
Need ultrasonic and warming)
晖光日新
Storage Store at -20°C六个核桃真的能补脑吗>天翼提速
General tips For obtaining a higher solubility , plea warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for veral months.
Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.
Structure
Background
如何说分手
Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50s of 1.5, 0.87 and 0.21 μM
鲤鱼跃龙门
Product Data Sheet
for human PPARα, PPARσ and PPARγ, respectively.
Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσand PPARγ[1]. Skin fibrosis is attenuated by Lanifibranor (IVA337) (p<0.05, vehicle vs
Lanifibranor at 30 mg/kg and p<0.001, vehicle vs Lanifibranor at 100 mg/kg). Both low and high dos of
Lanifibranor cau a significant decrea of collagenous matrix deposition. Administration of high (100 mg/kg) dos of Lanifibranor results in reduced body weight compare with vehicle controls (p<0.
05; Lanifibranor at 100 mg/kg vs vehicle). Results demonstrate that activation of Peroxisome proliferator-activated receptors (PPARs) with Lanifibranor induces a significant reduction in the infiltration of macrophages, CD45+ leucocytes and lymphocytes in
禁的拼音
Lanifibranor-treated mice compare with rosiglitazone-treated counterparts[2].
[1]. Boubia B, et al. Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. J Med Chem. 2018 Feb 27. [2]. Ruzehaji N, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016 Dec;75(12):2175-2183.
